Inmune Bio Stock Cash Flow From Operations
INMB Stock | USD 11.29 0.45 4.15% |
INmune Bio fundamentals help investors to digest information that contributes to INmune Bio's financial success or failures. It also enables traders to predict the movement of INmune Stock. The fundamental analysis module provides a way to measure INmune Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to INmune Bio stock.
INmune | Cash Flow From Operations |
INmune Bio Company Cash Flow From Operations Analysis
INmune Bio's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current INmune Bio Cash Flow From Operations | (11.98 M) |
Most of INmune Bio's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, INmune Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
INmune Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for INmune Bio is extremely important. It helps to project a fair market value of INmune Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since INmune Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of INmune Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of INmune Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Competition |
In accordance with the recently published financial statements, INmune Bio has (11.98 Million) in Cash Flow From Operations. This is 102.27% lower than that of the Biotechnology sector and 119.16% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 101.23% higher than that of the company.
INmune Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses INmune Bio's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of INmune Bio could also be used in its relative valuation, which is a method of valuing INmune Bio by comparing valuation metrics of similar companies.INmune Bio is currently under evaluation in cash flow from operations category among related companies.
INmune Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of INmune Bio from analyzing INmune Bio's financial statements. These drivers represent accounts that assess INmune Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of INmune Bio's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 59.6M | 206.4M | 164.5M | 113.7M | 202.5M | 101.6M | |
Enterprise Value | 52.8M | 184.6M | 105.0M | 76.8M | 177.1M | 185.9M |
INmune Fundamentals
Return On Equity | -0.61 | ||||
Return On Asset | -0.27 | ||||
Operating Margin | (299.25) % | ||||
Current Valuation | 178.91 M | ||||
Shares Outstanding | 18.77 M | ||||
Shares Owned By Insiders | 33.94 % | ||||
Shares Owned By Institutions | 13.19 % | ||||
Number Of Shares Shorted | 1.5 M | ||||
Price To Earning | (7.51) X | ||||
Price To Book | 4.91 X | ||||
Price To Sales | 1,208 X | ||||
Revenue | 155 K | ||||
Gross Profit | 374 K | ||||
EBITDA | (29.74 M) | ||||
Net Income | (30.01 M) | ||||
Cash And Equivalents | 61.21 M | ||||
Cash Per Share | 3.41 X | ||||
Total Debt | 10.44 M | ||||
Debt To Equity | 0.22 % | ||||
Current Ratio | 30.87 X | ||||
Book Value Per Share | 2.08 X | ||||
Cash Flow From Operations | (11.98 M) | ||||
Short Ratio | 14.76 X | ||||
Earnings Per Share | (1.67) X | ||||
Target Price | 19.67 | ||||
Number Of Employees | 11 | ||||
Beta | 1.95 | ||||
Market Capitalization | 211.97 M | ||||
Total Asset | 57 M | ||||
Retained Earnings | (121.02 M) | ||||
Working Capital | 21.48 M | ||||
Current Asset | 8.38 M | ||||
Current Liabilities | 721.01 K | ||||
Net Asset | 57 M |
About INmune Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze INmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of INmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of INmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out INmune Bio Piotroski F Score and INmune Bio Altman Z Score analysis. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.67) | Revenue Per Share 0.009 | Quarterly Revenue Growth (0.71) | Return On Assets (0.27) | Return On Equity (0.61) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.